Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)

Article ID	Journal	Published Year	Pages	File Type
6194079	Urologic Oncology: Seminars and Original Investigations	2014	9 Pages	PDF

Abstract

BSI and BSI changes over time were independently associated with OS in men with mCRPC. A delay in objective radiographic bone scan progression with TASQ is suggested; prospective evaluation of BSI progression and response criteria in phase 3 trials of men with mCRPC is warranted.

Keywords

progression-free survival Image analysis Automated detection Computer-assisted diagnosis Radionuclide imaging Prostate cancer Bone metastases

Related Topics

Health Sciences Medicine and Dentistry Oncology

Preview

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)

Authors

Andrew J. M.D., Sc.M, Reza Ph.D., Michael A. M.D., Jan-Erik M.D., Ph.D., Walter M. M.D., Mats Ph.D., Lars M.D., Ph.D., Göran Ph.D., Ãrjan B.Sc, Roberto M.D., Michael J. M.D.,